News

PaxMedica Announces Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301

The study’s primary endpoint was reached and demonstrated statistically significant and clinically meaningful resultsThese results pave the way for filing…

1 year ago

QIAGEN N.V. to release results for Q2 2023 and hold webcast

Venlo, The Netherlands, July 24, 2023 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans…

1 year ago

The Garry Hurvitz Centre for Community Mental Health at SickKids Selects VitalHub to implement its TREAT Client Information System to Enhance Client Care

TORONTO, July 24, 2023 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSX:VHI) (OTCQX:VHIBF) is excited to announce a…

1 year ago

SomaLogic partners with Dante Genomics to enhance clinical and research adoption of proteomics in Europe

SomaLogic’s 7,000-plex SomaScan® Platform will be used in proteomics testing at scale in EuropeBOULDER, Colo. and L’AQUILA, Italy, July 24,…

1 year ago

Quipt Home Medical to Participate at the 43rd Annual Canaccord Growth Conference

Fireside Chat to be Held Wednesday, August 9thCINCINNATI, July 24, 2023 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “Company”)…

1 year ago

Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement

Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement Biodexa Pharmaceuticals PLC (Nasdaq: BDRX),…

1 year ago

Tango Therapeutics Announces First Patient Dosed in TNG260 Phase 1/2 Trial in Patients With STK11-Mutant Cancers

BOSTON, July 24, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and…

1 year ago

Cara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7, 2023

STAMFORD, Conn., July 24, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment…

1 year ago

FibroGen to Report Second Quarter 2023 Financial Results

SAN FRANCISCO, July 24, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2023 financial results…

1 year ago